CatalystAlert

Search CatalystAlert

Search for companies, drugs, and catalysts

Search CatalystAlert

Search for companies, drugs, and catalysts

Pharmaceutical Technology
Original article

Eisai and CORE Biomedicine agree on global licence for oncology pipeline

PartnershipPositive
AI Analysis

Summary

Eisai has entered an exclusive global licensing agreement with CORE Biomedicine for several preclinical oncology programmes.

Importance:5/10
Sentiment:
0.50
licensingoncologypartnershippreclinical
Related Companies

Read the original article

Published by Pharmaceutical Technology on July 29, 2026 7:50 AM

Read Original